Tech Company Financing Transactions
Silarus Therapeutics Funding Round
On 9/23/2014, Silarus Therapeutics announced $10 million in Series A funding from Avalon Ventures and GlaxoSmithKline.
Transaction Overview
Company Name
Announced On
9/23/2014
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Avalon Ventures (Jay Lichter)
GlaxoSmithKline (Lon Cardon)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11099 North Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Co-Founder
Tomas Ganz
Browse more venture capital transactions:
Prev: 9/23/2014: Protenus venture capital transaction
Next: 9/23/2014: BetterWorks venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs